http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107488735-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6888 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 |
| filingDate | 2017-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107488735-B |
| titleOfInvention | MiR-339-5p is inhibiting the application in prostate cancer with osseous metastasis and TGF-β signal path |
| abstract | The invention discloses miR-339-5p to inhibit the application in prostate cancer with osseous metastasis and TGF-β signal path.The research of the invention finds that miR-339-5p low expression in prostate cancer with osseous metastasis, further study show that, miR-339-5p passes through SMAD2, SMAD3 and TGFBRI in targeting TGF-β signal path, inhibit TGF-β signal path activity, to inhibit the migration and invasion of Bone tumour precedent adenocarcinoma cell, therefore, miR-339-5p is expected to be applied to prepare prostate cancer with osseous metastasis diagnostic reagent, inhibits Bone tumour drug, TGF-β/smad inhibitor, SMAD2 inhibitor, SMAD3 inhibitor and TGFBRI inhibitor. |
| priorityDate | 2017-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 217.